From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
FAMILY | PATIENT | GENDER | AGE | ONSET | COURSE | CLINICAL MANIFESTATIONS | LABORATORY FINDINGS | PREVIOUS DIAGNOSES | TREATMENTS |
---|---|---|---|---|---|---|---|---|---|
1 | 1 | F | 62y | early childhood | relapsing-remitting | rA, HD, AA, PS | CRP/ESR ↑, ANA/ENA +, IFN-score - | HD, PA, RA, SS, SLE | steroids > adalimumab > tofacitinib |
2 | F | 32y | early childhood | relapsing-remitting | rA, rF, rI, CD, HD, AA, SK, PS, AH | CRP/ESR ↑, ANA/ENA -, IFN-score + | CD, AH, HD | steroids > azathioprine | |
3 | M | 10y | <1y | relapsing-remitting | rA, CD | CRP/ESR ↑, IFN-score + | none | steroids > colchicine | |
4 | M | 8y | <1y | relapsing-remitting | rA, rF, rI, GI, PS | CRP/ESR ↑, IFN-score + | PFAPA, IBD, BD | steroids > adalimumab | |
5 | F | 1y | <1y | relapsing-remitting | rA, rF, rI | CRP/ESR ↑, IFN-score + | none | steroids | |
2 | 6 | M | 22y | <1y | relapsing-remitting | rA, rF, rI, GI, AA, PS | CRP/ESR ↑, ANA/ENA -, IFN-score + | PFAPA, IBD, BD | steroids > adalimumab > apremilast |
3 | 7 | F | 2y | <1y | relapsing-remitting | rA, GI, AA, SK | CRP/ESR ↑, IFN-score + | IBD | steroids > anakinra > infliximab + methotrexate |